Navigation Links
Herborium Group Shareholders Update
Date:10/27/2011

SADDLE BROOK, N.J., Oct. 27, 2011 /PRNewswire/ -- Herborium Group, Inc., (Pinksheets: HBRM) www.herborium.com, a Botanical Therapeutics™ company, announced the following update today.

Dr. Agnes Olszewski, Chairmen and a CEO of Herborium stated: "These are truly exciting times for our Company. Firstly, we have continued our planned advancement to the Bulletin Board exchange by maintaining Herborium' Current Information Status– the highest tier attainable on OTC Pink Sheet Markets.  Additionally, we have many developments coming to fruition as a result of series of new initiatives we have undertaken in the Natural Medicine products space. These developments will play a significant role in Herborium's growth and future."

Dr. Olszewski continued, "As these developments are released to the public it will be important for all current and future shareholders to know what represents a value added and uniqueness of our Company, and where we are progressing along our business plan. Therefore, we felt it necessary to release a short overview of our business opportunity map, before we actually begin discussing the goals we have accomplished and those we are pursuing."

First and foremost Herborium is a natural medicinal products company with a number of established, proprietary, patent and/or trade secret protected natural medicinal products – Botanical Therapeutics®. Our Botanical Therapeutics are uniquely qualified and positioned to address numerous highly important health concerns in both the medical and social spaces. These products are differentiated from most of other natural medicinal products on a market by three distinct characteristics 1) scientific and clinical testing 2) each product targets high demand area of medical needs 3) intellectual property protection. In addition, number of our Botanical Therapeutics is beyond the development stage and is being commercialized or is ready for commercialization. Herborium has also secured a pipeline of product extensions that will assure the Company's positioning  in the marketplace and stream of revenues. The combined market for non-traditional treatments and healthy lifestyles expenditures in the USA alone exceeds $50 Billion with natural medicine being responsible for over 70% of the spending.  The overall potential for botanical drugs may exceed $3 trillion USD worldwide.

Herborium lead Botanical Therapeutic® - AcnEase® , (www.acnease.com is all botanical ingredients based medicine that addresses the need for an effective and safe solution  in the treatment of acne and symptoms of Rosacea.. The National Institute of Arthritis and Musculoskeletal and Skin Diseases Website (Division of National Institutes of Health) reports that in the US alone nearly 85% of people between the ages of 12 and 24 develop acne, and 60 million Americans have existing acne. Rosacea afflicts over 17 million Americans and is a much more prevailing problem in Europe with no known solution in sight.  AcnEase is an all natural systemic product that safely and effectively targets acne and Rosacea in both females and males of all ages.  The results of AcnEase have been impressive with up to 95% of patients seeing improvement after the first course of treatment. Those suffering from symptoms of Rosacea noted up to 90% improvement in skin related symptoms as well as GI and opthomological symptoms.

During the recent months, a significant progress has been made through our marketing efforts, with special focus on Social Marketing strategy, to capitalize on the unique benefits of AcnEase, and on growing consumer needs, exasperated by a recent withdrawal of the Roche Pharmaceutical product - Accutane , the only systemic competition for AcnEas, and by the increasing demand for natural medicines.

Those and other business progress milestones are going to be a subject in our forthcoming communications.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.  

One of our most important responsibilities is to communicate with shareholders in an open and direct manner.  Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends."  We cannot promise future returns.  Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.  The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: DrAgnes@Herborium.com


'/>"/>
SOURCE Herborium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... ... Research, a leading publisher of cannabis market research, the legal ... 27 percent CAGR through 2021, despite conflicting signals from the ... Analytics, points out that the two biggest drivers of growth ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... is very strong with a total of 97 drug candidates. Pharma giant ... are involved in the development of the IPF therapeutics. The IPF pipeline ... stage, 15 are in Phase II stage, 12 are in Phase I ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently becoming ... require expert user knowledge. In a live webinar on April 11th and October ... highly accurate, determination of sodium. , It has long been known that too ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/27/2017)... HOUSTON, Texas (PRWEB) , ... March 27, 2017 , ... ... and hard of hearing, is bringing its latest products to the Deaf Seniors of ... attendees will have the opportunity to meet with knowledgeable ASL friendly staff from Harris ...
Breaking Medicine News(10 mins):